Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$10.13M-72.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Howard W. Robin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Beta
- 1.15
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.57
Financials
Revenue
$10.13M-72.1%Net Income
$-40.62MEBITDA
$-42.24MFree Cash Flow
$-75.88MEPS (diluted)
$-1.23Shares Outstanding (diluted)
33.05M+261.7%Operating Expenses
$51.89MCash & Debt
$684.34MReturn of Capital
$0.00Revenue by Segment (annual)
$55.23MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $55.23M | $-164.08M | $-9.73 |
| 2024 | $98.43M | $-118.96M | $-8.68 |
| 2023 | $90.12M | $-276.06M | $-21.79 |
| 2022 | $92.06M | $-368.20M | $-29.51 |
| 2021 | $101.91M | $-523.84M | $-42.90 |
| 2020 | $152.91M | $-444.44M | $-37.33 |
| 2019 | $114.62M | $-440.67M | $-37.80 |
| 2018 | $1.19B | $681.31M | $56.70 |
| 2017 | $307.71M | $-96.69M | $-9.30 |
| 2016 | $165.44M | $-153.52M | $-16.50 |
| 2015 | $230.78M | $-81.18M | $-9.15 |
| 2014 | $200.71M | $-53.92M | $-6.30 |
| 2013 | $148.92M | $-162.01M | $-21.00 |
| 2012 | $81.19M | $-171.85M | $-22.50 |
Valuation
NKTRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
42-16.00%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·3d ago·Negative
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reactions, raising doubts about REZPEG's market potential in AA. NKTR maintains a strong cash position [$1.02B as of June 2026], sufficient to fund operations into Q3 2028, reducing near-term dilution risk.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program.
View source ↗ - Newsschaeffersresearch.com·4d ago·Neutral
3 Biotech Stocks Put Traders Are Targeting Today Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
View source ↗ - Newsprnewswire.com·5d ago·Positive
…any to host conference call with investors and analysts at 8:00 AM ET/2:00 PM CET SAN FRANCISCO and VIENNA, Oct. 1, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions. At EADV 2026, data from the 52-week treatment extension coho…
View source ↗ - Newsprnewswire.com·5d ago·Positive
…y as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further evidence that rezpegaldesleukin engages its regulatory Tcell (Treg)-mediated mechanism in patients with moderate-to-severe atopic dermatitis, with significant biom…
View source ↗ - Newsprnewswire.com·42d ago·Neutral
…ontinued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, prov…
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies, addre
View source ↗ - Newszacks.com·52d ago·Neutral
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Nektar Therapeutics Q2 Earnings Call Highlights Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.
View source ↗ - Newszacks.com·53d ago·Negative
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $2.78 per share a year ago.
View source ↗ - Newsprnewswire.com·53d ago·Negative
Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025.
View source ↗ - Newsdefenseworld.net·56d ago·Neutral
Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Nektar Therapeutics to post earnings of ($1.97) per share and revenue of $10.4250 million for the quarter. Investors may review the information on the company's upcoming Q2 2026 earning overview
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-2.10 per share
Typical surprise +28.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.23 vs $-1.97beat
- Thu, May 7$-1.82 vs $-1.58miss
- Thu, Mar 12$-1.78 vs $-2.47beat
- Thu, Nov 6$-1.85 vs $-2.85beat
- Thu, Aug 7$-2.95 vs $-3.03beat
- Thu, May 8$-3.60 vs $-2.56miss
Estimates and results for NKTR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NKTR officers and directors.
- Bought
- —
- Sold
- $3.8m
0 trades
55 trades
- Zalevsky Jonathansold
- Robin Howard Wsold
- Zalevsky Jonathansold
- Robin Howard Wsold
- Robin Howard Wsold
- Robin Howard Wsold
- Robin Howard Wsold
- Zalevsky Jonathansold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 2, 2018 (103d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 2, 2018 (118d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.